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ABSTRACT 
This is the j rs t  study of the intravascular iron oxide particle contrast agent, NC100150 Injection 
(Nycomed Imaging AS, Oslo, Norway, a part of Nycomed Amersham) in magnetic resonance imaging 
of the human heart. Eighteen healthy male volunteers were studied at both 0.5 and 1.5 T before and 
afier the administration of NC100150 Injection. Transaxial spin-echo images were acquired at both 
field strengths, conventional gradient-echo cine images at 0.5 T, and breathhold Turbo-FLASH cine 
images at 1.5 T. Optimized cine imaging sequences were used postcontrast, with a high flip angle of 
60-70”. In the spin-echo images there was a significant reduction in the blood pool flow artifact at 
the level of the right atrium (0.5 T, 57%, p < 0.01; 1.5 41%. p = 0.01) and the lej? ventricle (LV) 
(0.5 T, 45%, p = 0.01; 1.5 T, 45%, p < 0.01). In the conventional gradient-echo cines at 0.5 T, there 
was a signifcant increase in the LV blood pool and myocardial signal diffrence-to-noise ratio (SDNR) 
in the diastolic (56%, p = 0.01) and systolic (141%, p < 0.OOl)frames. There was also a significant 
increase in the signal intensity (SI) gradient at the LV blood pool-myocardial border in the dias- 
tolic and systolicframes (both p < 0.001). At higher doses of NClOO150 Injection (3 and 4 mg/kg), 
a rim of signal void around the LV blood pool was observed, perfectly defining the LV blood pool- 
myocardial border. In the Turbo-FLASH breathhold cines at 1.5 T, there was a significant increase 
in the LV blood pool-myocardial SDNR in the diastolic (221%, p < 0.001) and systolic (916%, p < 
0.001) frames. Again, there was also a significant increase in the SI gradient at the LV blood pool- 
myocardial border in the diastolic and systolicframes (both p = 0.003). In conclusion, NC100150 
Injection was given safely to 18 healthy subjects. Image qua@ and LV blood pool-myocardial defini- 
tion were improved after the administration of NClOOI50 Injection. These improvements enable better 
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spin-echo anatomical defiition, better definition of myocardial wall motion, and should improve the 
capability of automated edge detecdon algorithms. 
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INTRODUCTION 
Dynamic magnetic resonance (MR) angiography sig- 
nal-to-noise and image quality have been dramatically 
improved with the use of extracellular gadolinium-based 
contrast agents (1). The rapid clearance of extracellular 
contrast agents from the blood pool has limited their 
use in cardiac MR, where acquisition times and total 
scanning times remain relatively long. Furthermore, 
there is rapid myocardial uptake of extracellular gado- 
linium compounds, which limits the amount of blood 
pool-myocardial contrast seen with these agents in the 
heart (2). 
MR imaging now reprfsents the most accurate nonin- 
vasive method for measuring left ventricular (LV) vol- 
umes and mass (3,4). Conventional gradient-echo im- 
aging of the entire LV is time consuming, and breathhold 
techniques have been developed to reduce imaging times 
(5,6). These techniques use short echo times (TE) and 
repeat times (TR), which reduce the acquisition time but 
also reduce signal to noise. Manual image analysis can 
also be time consuming, and attempts hgve been made 
to automate this process (7,8). For accurate automated 
LV measurements, good blood pool-myocardial contrast 
is necessary. Thus, a contrasl agent that increases LV 
blood pool signal while the myocardial signal remains 
largely unchanged, and remains in the blood pool for long 
periods of time, would be useful for gradient-echo im- 
aging and automated image analysis. 
Intravascular contrast agents can be divided into three 
groups: gadolinium chelates, manganese chelates, and 
iron oxide particles (9). In this study we report the phase 
I preliminary MR findings for spin-echo and gradient- 
echo imaging of the heart, using for iron oxide particle 
contrast agent NC100150 Injection (Nycomed Imaging 
AS, Oslo, Norway, a part of Nycomed Amersham). 
MATERIALS AND METHODS 
Eighteen healthy male subjects were studied at 0.5 and 
1.5 T (9 subjects at each field strength, mean age 25 yr). 
Transaxial spin-echo images, from the level of the right 
pulmonary artery to the inferior border of the heart, and 
horizontal long-axis (HLA) gradient-echo cine images 
were acquired before and after the administration of 
NC 100 150 Injection. Three different doses of NC 100 150 
Injection (2,3, and 4 mg/kg) were given to three subjects 
at each field strength. All images were acquired with elec- 
trocardiogram gating. All subjects gave informed con- 
sent. 
Table I 
Spin-Echo Noise Data ( 2  SD) for All Doses of NC100150 Injection at 0.5 T and 1.5 T 
Aorta RA LV 
Pre Post Pre Post Pre Post 
0.5 T 
Noise 9 7 2 5 1  9 4 2 9 5  1472113 6 4 2 4 9  8 0 2 5 6  4 4 2 3 1  
f-test 0.90 co.01 0.01 
% noise reduction 4 57 45 
Noise 40 2 19 41 t 28 78 2 34 4 6 ?  18 1192 40 65 2 32 
t-test 0.90 0.1 (0.01 
9% noise reduction na 41 45 
1.5 T 
Noise was measured within the aorta, right atrium (RA), and left ventricle (LV) before and after the administration of 
NC100105 Injection. The r-test and Sb noise reduction compare data pre- and postcontrast at each level. 
na, not applicable. 
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Figure 1. Transaxial spin-echo images before and after the administration of NC100150 Injection. The image brightness and contrast 
settings are identical before and after contrast. Ao, level of aorta; RA, level of right atrium; LV, level of left ventricle. Image quality 
is improved by the reduction of the blood flow artifact. (A) Images acquired at 0.5 T (3 mglkg). (B) Images acquired at 1.5 T (4 
mglkg). Note in A that there is more respiratory artifact present in the precontrast than postcontrast images. 
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Imaging Protocol at 0.5 T 
Imaging was performed on an inhouse-designed mo- 
bile 0.5-T scanner, using a 2 k m 2  surface coil. An MR 
imaging console (Surrey Medical Imaging Systems, Sur- 
rey, UK) with additional hardware and software was 
used to generate and drive the gradient coils and radiofre- 
quency waveforms and to receive and reconstruct the im- 
age data. 
Spin-echo image parameters were as follows: 'IE 40 
msec, TR, RR interval, slice thickness (SLT) 10 mm, 
slices 10, field of view (FOV) 40 cm2, read matrix 256, 
number of excitations 02, phase matrix 128. Im- 
aging parameters were identical after contrast. Mean 
postcontrast imaging time was 46 min. 
Conventional gradient-echo image parameters were as 
follows: TE 8 msec, TR 40 msec, SLT 10 mm, FOV 40 
cm2, read 256, phase 128, NEX 2, frames 16. The flip 
angle was 4 5 O  before contrast and 70" after contrast. 
Mean postcontrast imaging time was 38 min. 
Imaging Protocol at 1.5 T 
Imaging was performed on a Picker Edge 1.5-T scan- 
ner (Picker, Cleveland, OH), using a phased array re- 
ceiver coil. Spin-echo image parameters were as follows: 
TE 22 msec, TR RR interval, SLT 5 mm, slice gap 5 
mm, slices 10, FOV 35 cm2, read 256, phase 128, NEX 
2. Imaging parameters were identical after contrast. M& 
postcontrast imaging time was 54 min. 
A segmented gradient-echo Turbo-FLASH sequence, 
acquired during a single breathhold (mean acquisition 
time 15 sec), was used for the HLA cine images. Parame- 
ters were as follows: TE 2.7 msec, TR 6 msec, SLT 10 
mm, FOV 35 cm2, read 256, phase 128, views per frames 
8, NEX 1, frames 12. The flip angle was 30" before con- 
trast and 60 after contrast. Mean postcontrast imaging 
time was 37 min. 
Image Analysis 
For the spin-echo images, blood pool noise was mea- 
sured (signal SD) before and after the administration of 
NC 100 150 Injection in three slices in the ascending aorta 
(Ao), right atrium (RA), and LV, respectively. The image 
quality was also subjectively scored by two observers: 1, 
very satisfactory; 2, satisfactory; 3, unsatisfactory; 4, 
very unsatisfactory. 
For the gradient echo images, a signal-to-noise ratio 
(SNR) was calculated for both the global LV blood pool 
and the LV myocardium, for the diastolic and systolic 
frames, before and after the administration of NC100150 
Injection. Noise was measured as the SD of the signal in 
a region of interest (ROI) outside the phase encode arti- 
fact. The ROI was placed in an identical position before 
and after contrast. A signal difference- (global LV blood 
pool signal minus myocardial signal) to-noise ratio 
(SDNR) was also calculated for the diastolic and systolic 
frames before and after the administration of NC100150 
Injection. The parameter SDNR was used because it pro- 
vides a display-independent parameter that gives equiva- 
lent information to a contrast-to-noise ratio (10). The first 
frame of the cine was used as the diastolic frame. A mea- 
surement of the image signal intensity (SI) gradient was 
made by assessing the image profile across the LV blood 
pool-endocardial border in the midseptum position. The 
gradient of each image profile was determined for a linear 
fit after correction for background noise. Overall, cine 
quality and myocardial wall definition in the septum, 
apex, and lateral wall were subjectively scored, using the 
scoring system above. - 
Parametric data were compared with the Student's 
t-test. Nonparametric - data were compared with the Wil- 
amla RA LV A. 
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Figure 2. Percentage change in the blood flow artifact noise 
in the aorta, RA, and LV for each of the doses of NC100150 
Injection (2, 3, and 4 mg/kg). (A) 0.5-T data, (B) 1.5-T data. 
At both 0.5 and 1.5 T there is a trend to a reduction in the noise 
in the aorta at the 4-mg/kg dose. At 1.5 T there is a trend at 
all levels to a higher noise reduction with the 4-mg/kg dose. 
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coxon signed-rank test. p < 0.05 was regarded as sig- 
nificant. 
RESULTS 
There were no major adverse reactions to NC100150 
Injection in any of 18 subjects after 14 days follow-up. 
There was no clinically significant change from baseline 
in the heart rate, systolic and diastolic blood pressures, 
oral temperature, respiration rate, or electrocardiograms 
(PR interval, the QRS duration, or the QT interval) during 
the study period at any of the three dose levels. No clini- 
cally significant changes were observed in the hematol- 
ogy and biochemistry parameters, the Ig and C levels, or 
the urinalysis. 
Spin-Echo Images 
There was a significant reduction in the blood pool 
flow artifact after the administration of NC100150 Injec- 
tion at the level of the RA (0.5 T, p < 0.01; 1.5 T, p = 
0.01) and LV (0.5 T, p = 0.01; 1.5 T , p  < 0.01) but not 
at the level of the Ao (0.5 T, p = 0.90; 1.5 T, p = 0.90) 
(Table 1, Fig. 1). The effect was more marked at the high- 
est dose; because of the small number of subjects at each 
dose, these differences were not statistically significant 
(Fig. 2) .  
The reduction in blood pool flow artifact by 
NC100150 Injection in the FL4 and LV was mirrored by 
a significant improvement of the subjective assessment 
of image quality at both field strengths (RA: 0.5 T. p = 
0.015 and 1.5 T, p = 0.011; LV: 0.5 T, p = 0.026 and 
1.5 T, p = 0.26). For the aorta there was a trend toward 
a subjective improvement in image quality at both field 
strengths. This probably reflects the reduction in blood 
pool artifact seen with the highest dose of NC100150 In- 
jection (Fig. 2) .  
Gradient-Echo Images 
Results at 0.5 T 
There was a small but insignificant increase in the LV 
blood pool S N R  in the diastolic ( p  = 0.77) and systolic 
( p  = 0.26) frames after the administration of NC100150 
Injection [Table 2, Fig. 3(A)]. However, for the LV blood 
pool-myocardial SDNR there was a significant improve- 
ment in both diastolic (p = 0.01) and systolic (p < 
0.001) frames after the administration of NC100150 In- 
jection (Table 2). 
Interestingly, there was a reduction in the blood pool 
SNR with higher doses of NC100150 Injection [Fig. 
4(A)]. Again, because of the small numbers involved, no 
significant difference in the S N R  between doses was ob- 
served. However, the SDNR was maintained at the higher 
dose, despite the reduction in the SNR, because of a con- 
cordant reduction in the myocardial signal (48% at 4 mg/ 
kg), which was not seen at the other doses (15% increase 
at 2 mg/kg, no change at 3 mg/kg) [Fig. 4(B)]. Further- 
more, with the higher doses of NC100150 Injection (3 
and 4 mg/kg), a rim of signal void was created, which 
was particularly helpful at defining the LV blood pool- 
myocardial border in the diastolic frames of these HLA 
cines (Fig. 5). 
SI gradients across the LV blood pool-endocardia1 
border showed an increase (i.e., better border definition) 
after the administration of NC100150 Injection in both 
Table 2 
Gradient-Echo LV Blood Pool SNR Data and LV Blood Pool-Myocardial SDNR Data 
for All Doses of NC100150 Injection at Both Field Strengths 
0.5 T 1.5 T 
Systole Diastole Systole Diastole 
Pre Post Pre Post Pre Post Pre Post 
SNR 3 3 2 1 2  3 4 2 1 1  2 4 2 9  2 7 2 6  1 0 2 2  1 8 5 2  8 2 1  1 6 2 4  
t-test 0.77 0.26 <0.001 <0.001 
% signal increase 3 10 7 2  95 
t-test 0.01 <0.001 <0.001 <0.001 
% signal increase 56 141 22 1 916 
SDNR 6 1 . 3  9 5 4  6 2 4  1 5 2 3  2 2 1  5 2 1  I t 1  8 ? 3  
The r-test and 70 signal increase compare data pre- and postcontrast for diastolic and systolic frames. 
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SI gradient increase was demonstrated between the given 
doses. 
Pre 
Pos 
A. Diastole Systole 
Pre 
Post 
B. Diastole Systole 
Figure 3. Horizontal long-axis gradient-echo images before 
and after the administration of NC100150 Injection. (A) Con- 
ventional gradient-echo images acquired at 0.5 T (2 mg/kg). 
(B) Breathhold Turbo-FLASH images acquired at 1.5 T (3 mg/ 
kg). The LV blood pool-myocardial border is clearly deline- 
ated in both systole and diastole after the administration of 
NC 100 150 Injection. However, the changes are best seen in the 
systolic frame at both field strengths. 
the diastolic ( p  < 0.001) and systolic ( p  < 0.001) frames 
(Table 3). Abrupt changes in SI gradient were seen at the 
3- and Cmg/kg doses related to the rim of signal void 
(Fig. 6),  but no statistically significant difference in the 
Results at 1.5 T 
There was a significant increase in both the LV blood 
pool SNR in the diastolic ( p  < 0.001) and systolic ( p  < 
0.001) fi-ames [Table 2, Fig. 3(B)] and the LV blood 
pool-myocardial SDNR in the diastolic ( p  < 0.001) and 
systolic ( p  < 0.001) frames (Table 2) after the adminis- 
tration of NC100150 Injection. 
There was no Significant difference between the given 
doses for the LV blood pool SNR and myocardial SNR 
[Fig. 4(A)]. There was a trend toward an increase in the 
LV blood pool-myocardium SDNR with increasing 
doses of NC100150 Injection [Fig. 4(C)]. However, be- 
cause of the small numbers involved, these differences 
between doses remained statistically insignificant. No 
rim of signal void around the LV blood pool was seen 
at 1.5 T at any of the doses of NC100150 Injection. 
SI gradients across the LV blood pool-endocardial 
border showed an increase after the administration of 
NC100150 Injection in both the diastolic ( p  = 0.003) 
and systolic ( p  = 0.003) frames (Table 3). The abrupt 
changes in SI gradient seen at 0.5 T, secondary to the 
rim of signal void, were not seen at 1.5 T. 
Qualiptive Results 
Qualitative score data for the overall HLA cine image 
quality correspond with the quantitative improvement in 
SDNR after NC100150 Injection (0.5 T, p < 0.01; 1.5 
T, p < 0.01). Qualitative comparison of the wall defini- 
tion after NC100150 Injection was also significant; lat- 
eral wall (0.5 T, p < 0.01; 1.5 T, p < O.Ol), apex (0.5 
T, p < 0.01; 1.5 T, p = 0.01), and septum (0.5 T, p < 
0.01; 1.5 T, p = 0.01). 
DISCUSSION 
The intravascular contrast agent NC100150 Injection 
was given safely to 18 healthy volunteers. No major ad- 
verse reactions were seen, although events including dys- 
pnea, abdominal pain, pruritus, headache, chest pain, in- 
jection site pain, and hypertension have been reported 
with other iron oxide-based contrast agents (1 1). 
NC100150 Injection lowers blood T1 to below 100 
msec for periods in excess of 2 hr in humans and has an 
R1 relaxivity of 20 mM/sec at 0.5 T (Kessler et al., per- 
sonal communication). It is thus well suited as a blood 
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Figure 4. (A) Percentage change in the LV blood pool S N R  in the diastolic and systolic frames at both field strengths for each 
of the doses of NC100150 Injection (2, 3, and 4 mglkg). (B) Percentage change in the LV blood pool myocardial SDNR in the 
diastolic and systolic frames at 0.5 T. (C) Percentage change in the LV blood pool myocardial SDNR in the diastolic and systolic 
frames at 1.5 T. 
pool contrast agent. With the Turbo-FLASH sequence 
(short TE and TR) used at 1.5 T, the T1 effects of 
NC 1001 50 Injection dominate the images, leading to an 
improvement in both the SNR and the SDNR after the 
administration of contrast. Furthermore, because blood 
pool saturation is reduced by NC100150 Injection, a high 
flip angle was used in the postcontrast sequence, reducing 
the myocardial signal and further enhancing the SDNR. 
The increase in the diastolic frame SDNR seen in this 
study was nearly twice that seen in the preliminary study 
of Stillman et al. (121, using Ferumoxtran (Advanced 
Magnetic Inc., Cambridge, MA) (221 versus 128%, ratio 
1.7) at 1.5 T, although it must be noted that the sequences 
differed in the two studies with a shorter TE and T1- 
weighting used in our study. There was a trend toward 
an increase in the SDNR with higher NClOOl50 Injection 
doses, related to the increase in T1 recovery. 
In the conventional gradient-echo images at 0.5 T, 
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Figure 5. Horizontal long-axis gradient-echo images at 0.5 T after the administration of NC100150 Injection. At the 3- and 4- 
mg/kg doses, a rim of signal void can clearly be seen delineating the LV blood pool-myocardial border. 
there was no significant increase in the SNR because of 
the long TE (8 msec) used, causing the T1 and T2* ef- 
fects to balance each other. However, with the high flip 
angle used in the postcontrast imaging sequence, myocar- 
dial signal was reduced, whereas the T1 properties of the 
contrast agent maintain the LV blood pool signal, im- 
proving the LV blood pool-myocardial SDNR. The 
SDNR increase for the diastolic (56 versus 26%, 'ratio 
2.2) and systolic (141 versus 67% ratio 2.1) frames was 
over twice that seen in the study of Pennell et al. (13), 
using gadopentetate dimeglumine (Magnevist, Berlex, 
Wayne, NJ) at 0.5 T. These differences can be accounted 
for by the lack of myocardial enhancement by the intra- 
vascular contrast agent. Furthermore, the improvement 
in contrast with gadopentetate dimeglumine is limited to 
20 min, whereas with NC100150 Injection, imaging can 
continue for up to 2 hr without reduction in blood pool 
enhancement. 
With increasing doses of NC100150 Injection at 0.5 
T, a rim of signal void was visualized, which further en- 
hanced the observer's ability to distinguish between the 
LV blood pool and the myocardium. This signal void is 
secondary to the cancellation of opposing phase spins in 
the contrast-enhanced blood pool and the myocardium, 
occumng in the &me pixel. The effect depends on the 
balance between the T1 and T2* effects of the agent, the 
dose given, and the sequence TE. Thus, if a sequence TE 
of 2 msec had been used, the rim signal void would not 
have been seen at any of the three doses, whereas if a 
TE of 12 msec had been used, the rim of signal void 
would have been present in at all doses used. 
Automated LV contour algorithms search for maxi- 
Table 3 
Midseptum LV Blood Pool-Endocardia1 SI Gradient Data for All Doses of NClOOlSO Injection 
at Both Field Strengths 
0.5 T 1.5 T 
Diastole Systole Diastole Systole 
Pre Post Pre Post Pre Post Pre Post 
SI gradient 1.5 2 0.9 6.0 2 3.0 1.6 2 0.9 5.5 2 2.4 0.7 2 0.3 2.1 2 0.9 0.8 2 0.4 2.9 5 1.6 
t-test <0.001 <0.001 0.003 0.003 
76 SI increase 29 1 242 184 276 
The z-test and % SI increase compare data pre- and postcontrast for diastolic and systolic frames. 
Cardiac M R  with Contrast Agent NC100150 Injection 31 
30 
25 
20 
15 
10 
Septum LV blood pool 
0 2 4 6 8 10 12 
Distance (rnm) 
Figure 6. Plots of SI image profiles (corrected for background 
noise) across the midseptum for diastolic images at 0.5 T (2 
and 4 mg/kg). The reduction in LV blood pool signal and rnyo- 
cardial signal are seen at the higher dose. However, the SI gradi- 
ent is greater at 4 mg/kg, secondary to the rim of signal void, 
which is represented by the signal dip seen in the 4-mglkg SI 
image profile. 
mum intensity gradients at the endocardia1 and epicardial 
borders (14). The significant improvement in the SI gra- 
dients across the LV blood pool-endocardial border after 
the administration of NC 100 150 Injection should there- 
fore improve automated segmentation capabilities. 
The spin-echo sequence uses a long TE and TR. T2* 
effects dominate, leading to a reduction in the blood pool 
flow signal artifact and an improvement in the image 
quality. As would be expected, there was a definite trend 
toward an increase in this effect with increasing dose of 
NC 100150 Injection, although this remained insignificant 
because of the small number of subjects studied. 
Study Limitations 
In general, it is good practice when studying contrast 
agents to compare the same sequence before and after 
contrast. However, it was believed that the optimal se- 
quence parameters should be used for both the pre- and 
postcontrast images. Thus, we used our currently opti- 
mized clinical sequence parameters for precontrast im- 
aging and a modified sequence (high flip angle) after con- 
trast. This postcontrast sequence had been previously 
optimized during phantom studies and was used to en- 
hance the T1-weighting of the image. If this high flip 
angle sequence had been used before contrast, very little 
signal would have been generated, and the results would 
have been further enhanced. 
CONCLUSIONS 
The intravascular iron oxide particle contrast agent, 
NC100150 Injection, can be given safely to humans at 
doses of between 2 and 4 mglkg. At these doses, there 
is an improvement in both qualitative and quantitative 
image parameters in conventional spin-echo images at 
0.5 and 1.5 T, conventional gradient-echo images at 0.5 
T and breathhold, and Turbo-FLASH gradient-echo im- 
ages at 1.5 T. 
Further studies are now required to identify the lowest 
administration dose, optimize pulse sequences, and estab- 
lish whether automated edge detection algorithms will be 
improved in the presence of NC100150 Injection in the 
blood pool. 
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